Categories: News

Xtant Medical to Present at the Canaccord Musculoskeletal Conference

BELGRADE, Mont., May 13, 2021 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, Chief Executive Officer, will present at the Canaccord Musculoskeltal Conference on Thursday, May 20, 2021, at 3:00 PM Eastern Time.

A live webcast of the presentation will be available on the Investors section of the Company’s website or through the conference site by using the link below.

Date: Thursday, May 20, 2021
Time: 3:00 PM ET
Webcast: Click Here

A replay of the webcast will be available for approximately 90 days on the Company’s website at www.xtantmedical.com following the conclusion of the presentation.

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Investor Relations Contact

David Carey
Lazar FINN
Ph: 212-867-1762
Email: david.carey@finnpartners.com 

Staff

Recent Posts

TestoPrime Review: Why TestoPrime Is Better Than Other Testosterone Booster Supplement in 2025?

TestoPrime is a top rated, all natural testosterone booster for men in their 40's and…

29 minutes ago

Lipozem Reviews: Does It Really Work For Weight Loss in 2025?

Lipozem: We Tested Lipozem Supplement - Here Is Our Honest Review NEW YORK CITY, NY…

29 minutes ago

Assessing Post-Cardiac Surgery Kidney Recovery Through PenKid’s Emerging Role in Renal Replacement Therapy Decisions

Proenkephalin A 119-159 (penKid) demonstrates potential as a predictor for successful discontinuation of continuous renal…

29 minutes ago

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Ad hoc announcement pursuant to Art. 53 LR Revenue Growth: Full-year 2024 revenue of €265.7…

4 hours ago

RiDYMO® Designs Cyclic Peptide for “Undruggable” β-Catenin Target Within Two Months

BEIJING, Jan. 8, 2025 /PRNewswire/ -- In a recent achievement, DP Technology's hit discovery platform RiDYMO® has…

6 hours ago